Neuland Laboratories is a Hyderabad-based pharmaceutical company making Active Pharmaceutical Ingredients and providing CDMO services to global pharma and biotech companies from three US FDA- and EU GMP-compliant facilities, serving clients in 80+ countries. This quarter's print will speak to whether margins hold above the 25% benchmark after Q1 FY27's 35.5%, and how the newly operational peptide Module 1 (7,000 L, $30 Mn invested) is converting its order book into commercial contracts.
| Results date | November 03, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 650.1 Cr |
| Previous quarter PAT | Rs. 147.4 Cr |
| Previous quarter EBITDA margin | 35.5% |
| Market cap | Rs. 24,679.61 Cr |
| CMP | Rs. 19,280.0 |
The Board of Directors will meet on Tuesday, November 3, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 (Regulation 29, SEBI LODR). The trading window has been closed since October 1, 2026, until 48 hours after the results declaration.
The quarter's central test is whether Neuland can build on a Q1 FY27 that management called 'broadly in line with our expectations' — total income of Rs. 650.1 Cr, up 116.3% YoY — while the sequential direction stays uncertain given management's warning that Q1 is not a normalized run-rate for the lumpy CDMO business. The peptide Module 1 went operational on September 15, 2026, inside the quarter, with $30 Mn invested and 7,000 L of reactor capacity, and management had said projects were ready to use the facility even before commissioning; the FY27 target of at least one commercial peptide NCE arrangement is the key item this quarter can advance. Working capital days of sale collapsed from 137 in Q4 FY26 to 84 in Q1 FY27, a 53-day improvement that achieved the FY27 normalization goal ahead of schedule. Europe contributed 47.31% and USA & North America 31.12% of Q1 FY27 revenue, so the rupee's 1.2% depreciation over the July-September quarter is a modest translation tailwind for the export-heavy book, while peers have flagged elevated raw-material and solvent costs as a mild margin headwind. The upcoming call is likely to cover the margin bridge versus the 25%-plus long-term benchmark, peptide order-book-to-contract conversion, and new capex approvals beyond the Rs. 1,460 Cr approved over the last 13 quarters.
Performance vs Guidance Tracking: Where management stands against its own stated targets:
Peptide Module 1 ramp and Module 2: The flagship strategic catalyst went live inside the quarter.
Strategic execution: Gland Pharma, Kakinada, R&D: Multiple growth investments are in flight, all funded from internal accruals.
Q2 FY27 run-rate vs Q1 lumpiness: Management explicitly said Q1 FY27 is not a normalized run-rate.
Risk follow-ups: US FDA and capital deployment: Compliance and returns questions to track on the call.
Management has said ~30% (the FY24 level) is within the business's realm and that better operating leverage and mix make such margins 'quite reasonable to assume', while cautioning that external factors and execution mix cause variations. The long-term benchmark is 25% plus EBITDA, with anything above considered a bonus.
Peptide Module 1 was declared operational on September 15, 2026, with $30 Mn invested and 7,000 L of reactor capacity, and management has said there is order-book visibility with projects ready to use the facility even before commissioning. However, management declined to quantify current-year peptide revenue given early-stage development projects, with 5-6 innovator engagements at an early stage and no revenue certainty.
Over the last 13 quarters, Rs. 1,460 Cr of capital investments have been approved with Rs. 870 Cr spent, including ~Rs. 203 Cr of new approvals in Q1 FY27 (of which Rs. 196 Cr is for Unit 1 strategic growth and capacity expansion). Peptide Module-1 plus Module-2 civil works are sized at Rs. 250-280 Cr, and a full large-scale peptide production suite would exceed Rs. 1,000 Cr.
Yes — Q1 FY27 total income of Rs. 650.1 Cr was up 116.3% YoY, and consolidated revenue from operations grew 119.15% YoY, driven by commercial CMS projects, operating leverage, and favorable customer mix. Management cautions the business is inherently 'lumpy', with Q1 falling 17.6% QoQ from Q4 FY26's exceptionally inflated Rs. 788.7 Cr.
A Form 483 with 1 observation on procedural improvements in water and environmental monitoring was issued after the August 10-14, 2026 inspection at Unit 3. The inspection was classified 'closed' with the Establishment Inspection Report (EIR) issued on October 14, 2026, with no adverse classification communicated.